A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
Completed · Phase 1 · NCT02651662
Conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $3,025
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 105
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- cemiplimab (drug), odronextamab (drug)
- Dates
- Started 2016-01-11; completion 2026-04-29
- Results posted
- Not yet
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body make…
From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $3,025 in research payments for this study in 2025 (6 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $3,025
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.